These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30486389)

  • 21. Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents.
    Mondal C; Halder AK; Adhikari N; Saha A; Saha KD; Gayen S; Jha T
    Eur J Med Chem; 2015 Jan; 90():860-75. PubMed ID: 25535952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fuzzy tricentric pharmacophore fingerprints. 1. Topological fuzzy pharmacophore triplets and adapted molecular similarity scoring schemes.
    Bonachéra F; Parent B; Barbosa F; Froloff N; Horvath D
    J Chem Inf Model; 2006; 46(6):2457-77. PubMed ID: 17125187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacophore modeling of human adenosine receptor A(₂A) antagonists.
    Xu Z; Cheng F; Da C; Liu G; Tang Y
    J Mol Model; 2010 Dec; 16(12):1867-76. PubMed ID: 20224910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of potent adenosine A2a antagonists as potential anti-Parkinson disease agents. Non-linear QSAR analyses integrated with pharmacophore modeling.
    Khanfar MA; Al-Qtaishat S; Habash M; Taha MO
    Chem Biol Interact; 2016 Jul; 254():93-101. PubMed ID: 27216633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FLEXS: a method for fast flexible ligand superposition.
    Lemmen C; Lengauer T; Klebe G
    J Med Chem; 1998 Nov; 41(23):4502-20. PubMed ID: 9804690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanomolar anti-sickling compounds identified by ligand-based pharmacophore approach.
    Paz OS; de Jesus Pinheiro M; do Espirito Santo RF; Villarreal CF; Castilho MS
    Eur J Med Chem; 2017 Aug; 136():487-496. PubMed ID: 28528302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Probabilistic Approach for Virtual Screening Based on Multiple Pharmacophores.
    Madzhidov TI; Rakhimbekova A; Kutlushuna A; Polishchuk P
    Molecules; 2020 Jan; 25(2):. PubMed ID: 31963467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Snooker: a structure-based pharmacophore generation tool applied to class A GPCRs.
    Sanders MP; Verhoeven S; de Graaf C; Roumen L; Vroling B; Nabuurs SB; de Vlieg J; Klomp JP
    J Chem Inf Model; 2011 Sep; 51(9):2277-92. PubMed ID: 21866955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel method for generating structure-based pharmacophores using energetic analysis.
    Salam NK; Nuti R; Sherman W
    J Chem Inf Model; 2009 Oct; 49(10):2356-68. PubMed ID: 19761201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ligand-based pharmacophore model of N-Aryl and N-Heteroaryl piperazine alpha 1A-adrenoceptors antagonists using GALAHAD.
    Zhao X; Yuan M; Huang B; Ji H; Zhu L
    J Mol Graph Model; 2010 Sep; 29(2):126-36. PubMed ID: 20538497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of pharmacophore similarity-based quantitative activity hypothesis and its applicability domain: applied on a diverse data-set of HIV-1 integrase inhibitors.
    Kumar SP; Jasrai YT; Mehta VP; Pandya HA
    J Biomol Struct Dyn; 2015; 33(4):706-22. PubMed ID: 24735019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ligand-based G Protein Coupled Receptor pharmacophore modeling: Assessing the role of ligand function in model development.
    Castleman P; Szwabowski G; Bowman D; Cole J; Parrill AL; Baker DL
    J Mol Graph Model; 2022 Mar; 111():108107. PubMed ID: 34915346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitor design against JNK1 through e-pharmacophore modeling docking and molecular dynamics simulations.
    Katari SK; Natarajan P; Swargam S; Kanipakam H; Pasala C; Umamaheswari A
    J Recept Signal Transduct Res; 2016 Dec; 36(6):558-571. PubMed ID: 26906522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pruned receptor surface models and pharmacophores for three-dimensional database searching.
    Sutherland JJ; O'Brien LA; Weaver DF
    J Med Chem; 2004 Jul; 47(15):3777-87. PubMed ID: 15239656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combining molecular dynamics simulation and ligand-receptor contacts analysis as a new approach for pharmacophore modeling: beta-secretase 1 and check point kinase 1 as case studies.
    Hatmal MM; Jaber S; Taha MO
    J Comput Aided Mol Des; 2016 Dec; 30(12):1149-1163. PubMed ID: 27722817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consensus superiority of the pharmacophore-based alignment, over maximum common substructure (MCS): 3D-QSAR studies on carbamates as acetylcholinesterase inhibitors.
    Chaudhaery SS; Roy KK; Saxena AK
    J Chem Inf Model; 2009 Jun; 49(6):1590-601. PubMed ID: 19441865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protein-ligand-based pharmacophores: generation and utility assessment in computational ligand profiling.
    Meslamani J; Li J; Sutter J; Stevens A; Bertrand HO; Rognan D
    J Chem Inf Model; 2012 Apr; 52(4):943-55. PubMed ID: 22480372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacophore, 3D-QSAR Models and Dynamic Simulation of 1,4-Benzothiazines for Colorectal Cancer Treatment.
    Rai A; Raj V; Aboumanei MH; Singh AK; Keshari AK; Verma SP; Saha S
    Comb Chem High Throughput Screen; 2017; 20(8):658-674. PubMed ID: 28486913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequence-derived three-dimensional pharmacophore models for G-protein-coupled receptors and their application in virtual screening.
    Klabunde T; Giegerich C; Evers A
    J Med Chem; 2009 May; 52(9):2923-32. PubMed ID: 19374402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combining 4D pharmacophore generation and multidimensional QSAR: modeling ligand binding to the bradykinin B2 receptor.
    Lill MA; Vedani A
    J Chem Inf Model; 2006; 46(5):2135-45. PubMed ID: 16995744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.